 The C. Dan Ebola virus, SUDV, outbreak highlights the need for increased research into emerging infectious diseases. Despite efforts by the Ministry of Health in Uganda and international support from the World Health Organization, the virus continues to spread to other regions, including the capital city. There is currently no licensed vaccine or therapeutics available, which poses a significant threat to public health. To date, only 20 SUDV research studies have been conducted, most of them in the United States. These studies focused primarily on therapeutics, vaccines, diagnostics, one health and social sciences. This limited research suggests a lack of investment in SUDV research, and an urgent need for further investment in developing effective vaccines and treatments for high-risk populations in affected regions. Investments should also focus on supporting outbreak control through access to these interventions.